
One minute to ignite new thinking in COPD
- Article
- Campus Sanofi
- Apr 1, 2024
This article discusses the role of blood eosinophils as a biomarker in patients with Chronic Obstructive Pulmonary Disease (COPD). It highlights that measuring blood eosinophil levels can help predict exacerbations, guide corticosteroid therapy, and tailor treatment strategies for COPD patients. The article emphasizes the importance of personalized treatment approaches based on eosinophil counts to improve patient outcomes and manage COPD more effectively.
Acute COPD exacerbations are linked to significant disease progression. Uncover criteria, symptoms, and treatment guidance to manage them in your patients.
Chronic Obstructive Pulmonary Disease (COPD), as defined by the Global Initiative for Chronic Obstructive Lung Disease (GOLD), is a heterogeneous lung condition characterized by chronic respiratory symptoms like dyspnea, cough, sputum, and exacerbations.1